Business
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
NEW YORK, August 19, 2025--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025.
About this update from Renova, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":200,"url":"https://media.zenfs.com/en/business-wire.com/8c131c944067a97e72404e4cac98f843"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/07heFudN1tLdf_SkmZ4YDw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8c131c944067a97e72404e4cac98f843","width":480,"height":200}},"lazy":false},{"type":"text","content":"Transforms present balance sheet with significant reduction in liabilities","length":74,"tagName":"p","attribs":{}},{"type":"text","content":"Largest shareholder is long-term strategic investor","length":51,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, August 19, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025.","length":471,"tagName":"p"},{"type":"text","content":""The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities," said TNF President and Chief Medical Officer, Mitchell Glass, M.D. "We are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF’s business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage."","length":528,"tagName":"p"},{"type":"text","content":"The improvements in the Company’s financial position will be reflected in future financial statements of the Company.","length":117,"tagName":"p"},{"type":"text","content":"About TNF Pharmaceuticals, Inc.","length":31,"tagName":"p"},{"type":"text","content":"TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only add...